Physician profile
Grant Kneeland Studebaker
NPI 1265774236
$27,498.64
in general payments reported to CMS, 2019-2025
17 companies · $9,903 in 2025
The $9,903 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $220 · 2021: $63.67 · 2022: $854 · 2023: $16K · 2024: $315 · 2025: $9,903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,690 · Food and Beverage: $1,343 · Consulting Fee: $1,070 · Travel and Lodging: $572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $15,552.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,690.00 |
| Food and Beverage | $1,343.41 |
| Consulting Fee | $1,070.00 |
| Travel and Lodging | $572.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $16,238.19 | 2022-2023 | Zimhi, Lucemyra |
| Alkermes, INC. | $9,950.35 | 2019-2025 | Vivitrol, Vivitrol |
| Indivior INC. | $518.17 | 2019-2025 | Sublocade |
| Braeburn INC. | $319.67 | 2023-2025 | Brixadi |
| Abbvie INC. | $79.61 | 2023-2025 | Vraylar |
| Glaxosmithkline, LLC. | $65.75 | 2022-2024 | Arexvy, Rotarix, Bexsero |
| Neurocrine Biosciences, INC. | $59.05 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $57.70 | 2025 | Auvelity |
| Pfizer INC. | $50.51 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.08 | 2022 | |
| Merck Sharp & Dohme LLC | $26.34 | 2022-2023 | Gardasil 9, Proquad, Vaxelis |
| Daiichi Sankyo INC. | $20.50 | 2021 | |
| Sobi, INC | $20.09 | 2020 | |
| Gilead Sciences, INC. | $20.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.91 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $12.53 | 2020 | |
| Avanir Pharmaceuticals, INC. | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Studebaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.